Alnylam Expands Asian Presence With RNAi License To Japan’s GeneDesign
This article was originally published in The Pink Sheet Daily
Executive Summary
“We’ve just scratched the surface” regarding plans for Asia, Alnylam Director of External Alliances Zimmerman tells “The Pink Sheet” DAILY.
You may also be interested in...
Alnylam Makes Entry Into Chinese RNAi Market
Cambridge, Mass., biopharma adds to Asian presence begun with Japanese licensing deal in October.
Alnylam Makes Entry Into Chinese RNAi Market
Cambridge, Mass., biopharma adds to Asian presence begun with Japanese licensing deal in October.
Alnylam Ends Relationship With Sirna Owner Merck
RNAi firm Alnylam terminated the relationship “to protect our intellectual property,” COO Greene tells “The Pink Sheet” DAILY.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: